Электроснабжение установки перекачки нефти п. Пионерный ОАО «Томскнефть»

РЕФЕРАТ Выпускная квалификационная работа 149 с., 23 рис., 32 табл., 29 источников, 6 прил. Ключевые слова: нефтепровод, насос, электрооборудование, схема электроснабжения, линия, сеть, электроприемник, нагрузка, оборудование, защита, ток, напряжение, мощность. Объектом исследования является электрическая часть УПН п. Пионерный ОАО «Томскенефть». Цель работы – проектирование схемы электроснабжения предприятия, выбор оборудования. В процессе исследования проводился сбор исходных данных в ходе производственной практики на объекте исследования. В результате была спроектирована схема электроснабжения от подстанции энергосистемы, до конечного электроприемника. Были выбраны кабели и провода, коммутационное оборудование, были сделаны необходимые проверки. Также результатом работы сталESSAY Final qualifying work 149 p., 23 fig., 32 tab., 29 sources, 6 adj. Keywords: oil, pump, electrical equipment, power supply circuit, line, network, power-consuming equipment, load equipment, protection, current, voltage, power. The object of research is the electrical part of UPN claim. Pionerny of "Tomskeneft". The purpose of work - designing enterprise power scheme, the choice of equipment. The study was conducted to collect baseline data in the course of practical training on the subject of the study. As a result, power supply circuit has been designed from the substation grid, appliance, to the end. Were selected cables and wires, switching equipment, the necessary checks have been made. It is also the result of the work became an economic calculation of capital costs for the con

Current potential and limitations of molecular diagnostic methods in head and neck cancer

Item does not contain fulltextTraditional diagnostic methods such as clinical assessment, histopathological examination and imaging techniques are limited in their capacity to provide information on prognosis and treatment choice of head and neck cancer. In recent years, molecular techniques have been developed that enabled us to get more insight into the molecular biological cellular pathways underlying tumor progression and metastasis. Correlation of these molecular changes with clinical events has been explored. However, consistently useful markers have not been identified yet, although many promising developments are in progress. It may be expected that in the near future, molecular markers will be useful for clinical purposes. In this paper, an overview will be given of the several molecular techniques that may have potential to be introduced in clinical practice in the management of head and neck squamous cell carcinoma.1 juni 201

International Consensus Statement on Rhinology and Allergy: Rhinosinusitis

Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS

927P Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: updated results from the real-world HANNA study [Abstract]

Background Real-world data for pts with R/M SCCHN receiving NIVO, particularly in the 1L setting, are limited. Here, we present updated results from the HANNA study (NCT03114163) that collected real-world data from pts with R/M SCCHN initiating NIVO treatment (tx) in the 1L or 2L+ settings in Germany. Methods This multicenter, prospective, non-interventional study included adults with R/M SCCHN progressing on or after platinum (Pt)-based therapy and treated with NIVO according to the approved label, including the 1L population (pts with Pt-sensitive or Pt-refractory disease who progressed > 6 or ≤ 6 months (mo) of Pt-based therapy, respectively). The primary objective was overall survival (OS); secondary objectives included duration of tx (DOT), time to next therapy (TTNT), and safety. Results This updated analysis (database lock: Jan 16, 2023) included data from May 2017–Jan 2023. Median follow-up was 44.4 mo. Baseline characteristics of the overall population (N = 478) and 1L subset (n = 223) were similar. Median (95% CI) OS was 10.5 (9.0–11.9) mo (overall) and 11.7 (9.5–13.7) mo (1L); median OS was similar in pts with Pt-refractory (11.9 mo [95% CI, 7.9–15.4]) and Pt-sensitive (11.2 mo [8.8–14.9]) disease in the 1L subset. OS by other subgroups is presented (Table). In the 1L subset, 36 (16.1%) pts received subsequent therapy, mainly cetuximab (n = 21; 58.3%). Median DOT was similar in the overall population (5.3 [95% CI, 4.0–5.8] mo) and 1L subset (5.4 [4.0–5.9] mo); median (range) TTNT was 21.0 (2.0–563.0) and 28.0 (3.0–563.0) days, respectively. Overall, any-grade and grade 3/4 tx-related or immune-related adverse events occurred in 156 (32.6%) and 57 (11.9%) pts, respectively. Conclusions Updated results from the real-world HANNA study continue to support NIVO as a safe and effective tx in the 1L or 2L+ settings for pts with R/M SCCHN in Germany